Citigroup Maintains Buy on GoodRx Holdings, Raises Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Daniel Grosslight maintains a Buy rating on GoodRx Holdings (NASDAQ:GDRX) and raises the price target from $7 to $11.
August 10, 2023 | 4:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup maintains a Buy rating on GoodRx Holdings and raises the price target from $7 to $11, indicating positive sentiment towards the stock.
The raised price target by Citigroup indicates a positive outlook for GoodRx Holdings. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100